Effectiveness of iron-based phosphate binders in reduction of hyperphosphataemia in chronic kidney disease patients


Chronic renal insufficiency
Ferric citrate
Iron-deficiency anaemia

How to Cite

Pokhrel, A., Chand, H., K.C., P. ., Shrestha, N., Ghimire, P. ., Ghimire, P., & Adhikary, L. P. (2023). Effectiveness of iron-based phosphate binders in reduction of hyperphosphataemia in chronic kidney disease patients. Journal of Kathmandu Medical College, 12(1), 10–16. Retrieved from https://jkmc.com.np/ojs3/index.php/journal/article/view/1264


Background: Ferric citrate is novel iron-based phosphate-binding drug for management of hyperphosphataemia and iron-deficiency anaemia in chronic kidney disease (CKD) patients.

Objectives: To evaluate impact of ferric citrate therapy on reduction of phosphate levels and improvement in haematological parameters in CKD stages 3-5.

Methods: This analytical, observational study was conducted at Kathmandu Medical College Teaching Hospital from 2020 July-December after ethical clearance using convenience sampling method. Non-dialysis dependent patients at CKD stages 3-5, having hyperphosphataemia (serum phosphate >=4.6mg/dL) and anaemia (serum haemoglobin <12 gm%, transferrin saturation <=30%, ferritin <=300ng/mL) were administered with 2gm twice daily dose of ferric citrate for 12 weeks and evaluated on outcomes in terms of reduction in serum phosphate levels and improvement in haematological parameters as study endpoints. Data were entered in Microsoft Excel and analysed in SPSS v.25. Significance level was set at p <0.05.

Results: Of 84 study participants, majority had CKD stage 4 (46, 54.76%). A significant reduction (p <0.001) in mean serum phosphate levels of 6.21 ± 1.062 mg/dL from baseline to 4.89 ± 1.100 mg/dL in 12-weeks was observed. Patients with CKD stages 3, 4, and 5 had mean reduction of 1.67 (p = 0.005), 1.40 (p <0.001), and 1.04 mg/dL (p = 0.002) of serum Phosphate level respectively. Significant (p <0.001) improvements in hemoglobin level, serum iron, ferritin, total iron binding capacity, and transferrin saturation were reported.

Conclusion: Ferric citrate is effective and well-tolerated phosphate-binder to improve hyperphosphataemia and iron deficiency anaemia in non-dialysis CKD stage 3, 4, and 5.



Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P. Mild hyperphosphataemia and mortality in haemodialysis patients. Am J Kidney Dis. 2005 Jul;46(1):68-77. [PubMed | Full Text | DOI]

Delmez JA, Slatopolsky E. Hyperphosphataemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis. 1992 Apr;19(4):303-17. [PubMed | Full Text | DOI]

Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol. 2009 Feb;20(2):397-404. [PubMed | Full Text | DOI]

Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis. JAMA. 2011 Mar 16;305(11):1119-27. [PubMed | Full Text | DOI]

Fishbane S, Spinowitz B. Update on anaemia in ESRD and earlier stages of CKD: Core curriculum 2018. Am J Kidney Dis. 2018 Mar;71(3):423-35. [PubMed | Full Text | DOI]

Rees L, Shroff RC. Phosphate binders in CKD: Chalking out the differences. Pediatr Nephrol. 2010 Mar;25(3):385-94. [PubMed | Full Text | DOI]

Drüeke TB, Parfrey PS. Summary of the KDIGO guideline on anaemia and comment: Reading between the (guide)line(s). Kidney Int. 2012 Nov;82(9):952-60. [PubMed | Full Text | DOI]

Fishbane S. Iron supplementation in renal anaemia. Semin Nephrol. 2006 Jul;26(4):319-24. [PubMed | Full Text | DOI]

Department of health services. National treatment protocol for renal diseases and renal replacement therapy. Government of Nepal; 2019. Available from: http://dohs.gov.np/wp-content/uploads/2019/02/TREATMENT-PROTOCOL-RENAL-DISEASES.pdf [Full Text]

Sim JJ, Bhandari SK, Smith N, Chung J, Liu IL, Jacobsen SJ, et al. Phosphorus and risk of renal failure in subjects with normal renal function. Am J Med. 2013 Apr;126(4):311-8. [PubMed | Full Text | DOI]

Zoccali C, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol. 2011 Oct;22(10):1923-30. [PubMed | Full Text | DOI]

Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012 Aug;23(8):1407-15. [PubMed | Full Text | DOI]

Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anaemia and reduction of serum phosphate in patients with CKD Stages 3-5. Am J Kidney Dis. 2015 May;65(5):728-36. [PubMed | Full Text | DOI]

Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant. 2002 Feb;17(2):265-70. [PubMed | Full Text | DOI]

Li L, Zheng X, Deng J, Zhou J, Ou J, Hong T. Ferric citrate for the treatment of hyperphosphataemia and anaemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials. Ren Fail. 2022 Dec;44(1):1112-1122. [PubMed | Full Text | DOI]

Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, et al. Ferric citrate hydrate for the treatment of hyperphosphataemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014 Mar;9(3):543-52. [PubMed | Full Text | DOI]

Kidney disease: Improving global outcomes (KDIGO) CKD-MBD work group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009 Aug;(113):S1-130. [PubMed | Full Text | DOI]

Chertow GM, Block GA, Neylan JF, Pergola PE, Uhlig K, Fishbane S. Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease. PLoS One. 2017 Nov 29;12(11):e0188712. [PubMed | Full Text | DOI]

Nand N, Giri K, Jain D. Role of ferric citrate in hyperphosphataemia and iron deficiency anaemia in non-dialysis CKD patients. J Assoc Physicians India. 2019 Apr;67(4):53-6. [PubMed | Full Text]

Yokoyama K, Hashimoto T, Okuda Y, Matsumoto Y, Ito K, Yamada R, et al. Safety and effectiveness of ferric citrate hydrate in serum phosphorus management of patients with chronic kidney disease: A long-term, real-world, observational, post-marketing surveillance study. Clin Exp Nephrol. 2022 Jul;26(7):688-699. [PubMed | Full Text | DOI]

Vaziri ND. Understanding iron: Promoting its safe use in patients with chronic kidney failure treated by haemodialysis. Am J Kidney Dis. 2013 Jun;61(6):992-1000. [PubMed | Full Text | DOI]

Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. 2015 Oct;26(10):2578-87. [PubMed | Full Text | DOI]